z-logo
Premium
Attrition‐Enhanced Deracemization of the Antimalaria Drug Mefloquine
Author(s) -
Engwerda Anthonius H. J.,
Maassen Rick,
Tinnemans Paul,
Meekes Hugo,
Rutjes Floris P. J. T.,
Vlieg Elias
Publication year - 2019
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201811289
Subject(s) - mefloquine , enantiomer , drug , malaria , pharmacology , racemic mixture , chemistry , combinatorial chemistry , plasmodium falciparum , stereochemistry , medicine , immunology
Mefloquine is an important drug for prevention and treatment of malaria. It is commercially available as a racemic mixture, wherein only one enantiomer is active against malaria, while the other one causes severe psychotropic effects. By converting the drug into a compound that crystallizes as a racemizable racemic conglomerate, the deracemization of mefloquine into the desired enantiomer was achieved.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here